A new research has revealed that an ovarian cancer pill for women might provide a highly effective treatment for up to a third of men with advanced prostate cancer.
The ovarian cancer, 'Olaparib,' is the first drug which was used to tackle inherited cancer mutations.
Researchers at Institute of Cancer Research found it could also halt tumour growth in many men with treatment-resistant prostate cancer, The Independent reports.
The study included 49 men and one third responded to the drug.
According to the results, cancers stopped growing, numbers of circulating tumour cells in the blood fell, and clinically positive results were obtained from scans.
The blood marker used to track the progress of prostate cancer also plunged by up to 96 percent.
Lead researcher Johann de Bonosaid said that their trial marked a significant step forward in the treatment of prostate cancer.
Bono said that it also proved the principle that they could detect prostate cancers with specific targetable mutations using genomic sequencing to deliver more precise cancer care by matching treatment to those men most likely to benefit.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
